Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Ex Vivo Lung Perfusion Yields Good Donor Lungs

By HospiMedica International staff writers
Posted on 25 Apr 2011
The use of normothermic ex vivo lung perfusion (EVLP) to make suboptimal donor lungs more viable for transplant yields clinical outcomes similar to those obtained with conventionally selected lungs, according to a new study.

Researchers at the University of Toronto (Canada) conducted a prospective, nonrandomized clinical trial, subjecting lungs considered to be high risk for transplantation to four hours of EVLP. More...
High-risk donor lungs were defined by specific criteria, including pulmonary edema and a ratio of the partial pressure of arterial oxygen (PO(2)) to the fraction of inspired oxygen (FIO(2)) of less than 300 mmHg. Lungs with acceptable function were subsequently transplanted; lungs that were transplanted without EVLP during the same period were used as controls. The primary end point was graft dysfunction 72 hours post-transplantation. Secondary end points were 30-day mortality, bronchial complications, duration of mechanical ventilation, and length of stay in the intensive care unit (ICU) and hospital. A total of 136 lungs were transplanted.

The results showed that during the study period, lungs from 23 donors met the inclusion criteria for EVLP; in 20 of these lungs, physiological function remained stable during EVLP and the median PO(2):FIO(2) ratio increased from 335 mmHg in the donor lung to 414 and 443 mmHg at one hour and four hours of perfusion, respectively; the other 116 lungs constituted the control group. The incidence of primary graft dysfunction 72 hours after transplantation was 15% in the EVLP group compared to 30% in the control group. No significant differences were observed for any secondary end points, and no severe adverse events were directly attributable to EVLP. The study was published in April 14, 2011, issue of the New England Journal of Medicine (NEJM).

"Extracorporeal resuscitation of lungs is likely to be useful for expanding access to donor lungs. The future, I think, is that the device can be used to treat the lungs with medications to reverse the causes of lung dysfunction, and perhaps to treat infections that currently prevent us from using some donor lungs,” said lead author Marcelo Cypel, MD, of the Toronto Lung Transplant Program at the University of Toronto. "In principle, EVLP could also be used to administer gene therapy or other treatments to improve long-term outcomes after transplant. It's exciting to see this turning into something we can use for patient care.”

An EVLP system involves perfusion of the lungs outside of the body with a dilute blood supply containing a solution that can potentially recondition and improve their function; the apparatus also includes a ventilator to inflate the lungs. The system permits the re-expansion of collapsed lung regions; removal of secretions; removal of clots from the lung circulation; improved lung ventilation; and a better and more complete assessment of lung function.

Related Links:
University of Toronto



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Fetal Monitor
BT-380
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.